Phase 1 safety and pharmacokinetics studies of BRII-196 and BRII-198, SARS-1 CoV-2 spike-targeting monoclonal antibodies 2 3 Yao Zhang^{1,3,¶}, Xiaohua Hao^{2,¶}, Ji Ma³, Mingming Wang³, Yanyan Li³, Yang Liu³, Dong 4 Zhao², Wen Zhang², Chunming Li³, Li Yan³, Qing Zhu^{1,3,*}, Fujie Zhang^{2,*} 5 6 ¹ TSB Therapeutics, Beijing, China 7 ² Beijing Ditan Hospital, Capital Medical University, Beijing, China ³ Brii Biosciences Inc., Durham, NC, US 9 10 *: Correspondening authors: 11 12 Qing Zhu Email address: ging.zhu@briibio.com (QZ) 13 Fujie Zhang 14 Email address: treatment@chinaaids.cn (FZ) 15 16 17 These authors contributed equally to this work. Running title: Safety and PK of COVID-19 mAbs in human 18 19 Abstract: 189/200 words Text: 2546/3500 words 20 Potential conflicts of interest: authors were employees of TSB therapeutics, Brii 21 22 Biosciences, or Ditan Hospital when the study was conducted Financial support: This study was sponsored by TSB Therapeutics, a subsidiary 23 company of Brii Biosciences 24 25 26

Abstract

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

Background. BRII-196 and BRII-198 are two anti-SARS-CoV-2 monoclonal neutralizing antibodies with modified Fc region that extends half-life and are being developed as cocktail therapy for the treatment of COVID-19. Safety, tolerability, pharmacokinetics, and immunogenicity of BRII-196 and BRII-198 were investigated in healthy adults. Methods. Single ascending doses of BRII-196 and BRII-198 were evaluated in parallel in the first-in-human, placebo-controlled phase 1 studies. A total of 32 healthy adults were randomized and received a single intravenous infusion of 750, 1500, and 3000 mg of BRII-196 (n=12), BRII-198 (n=12), or placebo (n=8) and were followed for 180 days. Results. All infusions were well tolerated at infusion rates between 0.5 mL/min to 4 mL/min with no dose-limiting adverse events, deaths, serious adverse events, or any systemic or local infusion reactions. Most treatment-emergent adverse events were isolated asymptomatic laboratory abnormalities of Grade 1-2 in severity. Each mAb displayed pharmacokinetics expected of Fc-engineered human IgG1 with mean terminal half-lives of approximately 46 days and 76 days, respectively, with no evidence of significant anti-drug antibody development.

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

Conclusions. BRII-196 and BRII-198 were well-tolerated. Clinical results support further development as therapeutic or prophylactic options for SARS-CoV-2 infection. **Keywords.** SARS-CoV-2; monoclonal antibody therapy; BRII-196; BRII-198 Clinical Trials Registration. NCT04479631 and NCT04479644 Funding: These studies were sponsored by TSB Therapeutics. **Background** As of March 2021, globally, over 120 million people have been infected by SARS-CoV-2, resulting in more than 2.6 million death by Coronavirus Disease 2019 (COVID-19). The number of cases continues to rise[1]. The development of safe and effective therapeutics represents a key strategy to curb COVID-19 mortality and morbidity. Several approved medications (e.g., chloroquine, hydroxychloroquine, lopinavir/ritonavir) have been "repurposed" and evaluated, none of which have been shown associated with improved clinical outcomes[2, 3]. There have been limited treatment options, including remdesivir, dexamethasone, and convalescent plasma, that demonstrated clinical efficacy in subsets of patients with COVID-19[4-7]. Neutralizing monoclonal antibodies (mAbs) represent a promising therapeutic option in preventing and treating known and emerging infectious diseases, including viruses[8]. Recent clinical trials of mAbs reported positive results indicating virological and clinical benefits among outpatients with COVID-19 [9, 10]. In addition, several COVID-19 vaccines offering>90% protection have become available

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

for emergency use [11, 12]. However, recent data showed that several mutations identified in the receptor binding domain (RBD) of spike protein in the emerging new variants conferred reduced activity to neutralization by the antibodies that were developed as a therapy for treatment or elicited by vaccines for prevention [13, 14]. These emergent variants present new challenges for mAb therapy and threaten the protective efficacy of current vaccines and mAbs. Therefore, additional mAb treatment options, especially a cocktail of antibodies targeting distinct epitopes, are needed as a critical strategy to reduce the generation and selection of resistant viruses during treatment and ensures binding and neutralization of the antibodies to new variants. BRII-196 and BRII-198, two recombinant human IgG1 mAbs that target the distinct epitope regions in RBD in coronavirus spike glycoproteins non-competitively, are under clinical development as a cocktail for the treatment of COVID-19 in outpatients. BRII-196 and BRII-198 are derived directly from human B cells of patients who recovered from COVID-19 [15] with effective neutralizing activity against not only the original isolate of SARS-CoV-2 but also the new variants of concerns, including B.1.351 (as known South African variant) and P1 from Brazil [16, 17]. BRII-196 and BRII-198 are engineered with a triple-amino-acid (M252Y/S254T/T256E [YTE]) substitution in the fragment crystallizable (Fc) region to allow an extended half-life [18, 19] and reduced Fcy receptor binding for potential risk of Fc-medicated antibody dependent enhancement (ADE) (unpublished data). The back-to-back first-in-human phase 1 studies in healthy adult participants were designed and conducted to evaluate the safety, tolerability, and pharmacokinetics (PK) of BRII-196 and BRII-198 individually before initiating clinical studies of BRII-196 and BRII-198 in combination in patients.

Methods

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

Study design and participants BRII-196-001 and BRII-198-001 are two first-in-human phase 1, randomized, singleblind, placebo-controlled, single ascending dose escalation studies in which BRII-196 and BRII-198 were evaluated respectively among healthy adults. These studies were conducted at a single phase 1 unit in China from July 2020 to February 2021 (registered at ClinicalTrials.gov under registration number NCT04479631 and NCT04479644). The study protocol, amendments, and informed-consent forms were reviewed and approved by Ethical Review Committee at the site. This study was conducted in accordance with the International Conference on Harmonisation Guidance for Good Clinical Practice guidelines and all applicable local regulatory requirements and laws. Participants provided written informed consent before any study-related procedures were performed. Inclusion and exclusion criteria for the two studies were identical. Eligible participants were healthy male or female adults aged 18 to 49 years, had a body weight <100 kg and a body mass index of 18-24 kg/m², and were in good health determined by no clinically significant findings from medical history, physical examination including vital signs, electrocardiogram (ECG), and clinical laboratory assessments. Women were not pregnant or lactating. Exclusion criteria included a history of SARS-CoV-2 infection or exposure, a history of severe allergic reactions, use of any medications that were started within 14 days before randomization, a positive test for human immunodeficiency virus (HIV) or hepatitis B virus or hepatitis C virus, a history of drug or alcohol abuse within 1 year before the screening, or any history of a medical or psychiatric condition that would place them at risk or interfere

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

with study participation. Participants were also excluded if they were unwilling to use necessary contraception during the study. A complete list of exclusion criteria is included in Supplementary Material 1. **Study Procedures** Three dose-level cohorts (750, 1500, and 3000 mg) were included to evaluate each mAb and were initiated in a dose-escalation design. In each cohort, participants were randomized at a 3:1 ratio to receive either the single mAb (n=3 or 6) or placebo (n=1 or 2). mAbs or placebo was dispensed into normal saline and was administered via intravenous infusion on Day 1. The infusion started at the initial rate of 0.5 mL/min, gradually increasing to a maximum rate of 4 mL/min. The participants were masked to the treatment assignment and were admitted to the phase 1 unit for monitoring for 7 days post-dosing. The first participant in each cohort who received mAb infusion was monitored for 24 hours before administering study intervention to the subsequent participants. A Safety Review Committee made Dose-escalation recommendations upon review of predefined safety data. Vital signs, physical examinations, safety laboratory tests including hematology and chemistry, and ECG were obtained before and after study drug administration on days 2, 4, 6, 8, 15, 22, 31, 61, 91, 121, 151, and at the end of the study on day 181. All adverse events (AEs), including infusion reactions and serious adverse events (SAEs) occurring throughout the trial, were recorded and assessed by study physicians at the site. AEs were coded with the Medical Dictionary for Regulatory Activities (MedDRA) version 23.1, and severity was graded using the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0, November 27, 2017.

Pharmacokinetics and Immunogenicity Assessments

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

The pharmacokinetics parameters were evaluated using blood samples collected before dosing, at 3 and 8 hours post dose, and days 2, 4, 6, 8, 15, 22, 31, 61, 91, 121, 151, and 181. BRII-196 or BRII-198 serum concentrations were measured using validated enzyme linked immunosorbent assays (ELISA) with the lower limit of quantitation (LLOQ) at 150 ng/mL. Serum samples for anti-drug antibody (ADA) assays were collected at the following time points: pre-dose on day 1 and at days 15, 31, and 181. Two validated titer-based 3-stage ELISA assays were used to detect presences of ADAs from subjects over the study durations. **Study Outcomes** Primary endpoints were incidence of adverse events (AEs) and change from pre-dose baseline in clinical assessments, including vital signs, ECG readings, and laboratory results. Secondary endpoints included the pharmacokinetics profiles and presence of ADAs to BRII-196/BRII-198 in samples collected after dosing for up to 180 days. **Statistical Analysis** The sample size of each study was consistent with a phase 1 first-in-human study. The safety analysis included all participants who were randomized and received any dose of the study drug. Categorical and continuous data were summarized descriptively. Participants were analyzed according to the study drug they received. Participants receiving placebo in different cohorts of each study were pooled in the analysis. The PK parameters were estimated by non-compartmental analyses using WinNonlin module in the Phoenix Platform (version 8.3.1.5014, Certara Inc., Princeton, NJ 08540). Calculations were performed prior to rounding, and nominal sampling times were used in the pharmacokinetic analysis. All pharmacokinetic parameters and

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

summary statistics are reported to 3 significant digits except for T_{max} (reported in median values), which is reported to 1 decimal place. **Results** From July 12, 2020, to August 10, 2020, a total of 135 participants were screened, with 16 and 17 eligible and enrolled for BRII-196-001 and BRII-198-001 studies, respectively (Figure 1). The demographics of the study population are summarized in **Table 1**, consisting of 28 (84.8%) men and 5 women with a median age of 33.0 years and a median BMI of 21.9 kg/m^2 . A total of 12 participants received a single dose of BRII-196 IV infusion, 12 participants received a single dose of BRII-198 IV infusion, and 8 participants received placebo (normal saline). One participant randomized in BRII-198-001 study did not receive the infusion because of elevated blood pressure before dosing. All participants received their full planned dose except for 3 participants assigned to 750 mg of BRII-196 and 1 participant assigned to placebo for whom the received volume was approximately 10% less than the intended volume due to the remaining volume left within the infusion set. All participants dosed have completed study visits. Total infusion duration for BRII-196 or BRII-198 at investigated dose levels were 1.53-1.70 hours (750 mg), 2.27-2.43 hours (1500 mg), and 3.58-3.75 hours (3000 mg) (Supplementary Table 1). **Safety** BRII-196 and BRII-198 administration was safe and well-tolerated. No deaths, serious AEs, treatment-emergent adverse events (TEAEs) leading to early termination, or infusion-related reactions occurred during the study. Adverse events

reported in BRII-196-001 and BRII-198-001 are summarized in **Table 2** and **Table 3**, respectively. 26 (81%) participants had at least one treatment-emergent adverse events, including 18 (75%) participants receiving BRII-196 or BRII-198 compared to 8 (100%) participants receiving placebo. Overall incidences of adverse events were balanced between groups receiving BRII-196 or BRII-198 and placebo. The most common TEAEs were isolated asymptomatic laboratory abnormalities of CTCAE Grade 1 or 2 in severity that did not require medical intervention and typically normalized or returned to baseline level within four weeks (Supplementary Table 2). Seven out of 24 participants had 8 Grade 1 or 2 adverse events that were considered by the investigators as related to BRII-196 or BRII-198, including increased blood total bilirubin, increased alanine aminotransferase, decreased neutrophil count, and decreased white blood cell count (Supplementary Table 3). No safety issues were seen with respect to vital signs or ECG measurements. No dose-dependent pattern of any adverse events was observed.

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

Pharmacokinetics Pharmacokinetic data were available for a total of 12 participants each for BRII-196 and BRII-198 over the 181-day study duration. Following a single intravenous infusion of BRII-196 or BRII-198 at 750, 1500, and 3000 mg, mean serum PK parameters, including C_{max} and AUC, increased in an approximately doseproportional manner (Table 4, Figure 2). The mean systemic serum clearances were 75.4 and 57.0 mL/day for BRII-196 and BRII-198, respectively. The mean terminal half-lives $(t_{1/2})$ of BRII-196 and BRII-198 were 44.6-48.6 days and 72.2-83.0 days. The relatively shorter terminal half-life of BRII-196 correlated with slightly higher systemic clearance. **ADA Response** In BRII-196-001 study, a total of 4 out of 12 participants had positive ADA samples in the screening assay, but all tested negative in the follow-up confirmatory assay. In BRII-198-001 study, one participant who received BRII-198 had positive ADA samples in the screening assay but later confirmed negative in the tier-2 confirmatory assay. **Discussion** BRII-196 and BRII-198 are fully human mAbs that bind to noncompeting epitope regions on the RBD of SARS-CoV-2 S glycoprotein that interacts with the angiotensin-converting enzyme 2 (ACE2) to enter human cells [20]. Therefore, they neutralize virus infection by preventing virus binding to ACE2, blocking virus entry and subsequent virus infection as demonstrated in vitro and in vivo [15, 21]. The

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

combined use of 2 independently neutralizing antibodies is likely to reduce the risk of treatment failure from the development of virus escape mutants or new variants that may arise during an outbreak. Currently approved COVID -19 vaccines were constructed against the original virus, of which attenuation of serum neutralization activity has been observed[14, 22]. In a recent trial conducted in South Africa, the ChAdOx1 nCoV-19 vaccine did not protect against mild-to-moderate COVID-19 due to the B.1.351 variant [23]. Pseudo viruses harboring mutations found in B.1.351 South Africa origin, P.1 Brazil origin, B.1.526 New York origin, L452R, and the spike protein from the California origin variant lineage B.1.427/B.1.429, had significantly reduced susceptibility to bamlanivimab [24], a mAb authorized for emergency use. In addition, its approved cocktail with etesevimab under EUA was also tested inactive against the live virus of B.1.351 South Africa [17]. As some of these variants are beginning to spread around the world, it has posed a real threat to vaccine and antibody therapies. By contrast, BRII-196 and BRII-198 cocktail retained their neutralizing activity against all variants tested, including B1.1.7 UK variant, B1.357 South Africa variant, and P1 Brazilian variants[16, 17], thereby could provide more treatment options to patients. In these first-in-human clinical studies, intravenous administration of BRII-196 and BRII-198 were both safe and well-tolerated in healthy adult participants receiving a single dose up to 3000 mg, with no infusion reactions or AEs leading to adjustment or discontinuation of the infusion. Study participants were followed up to 180 days postdosing considering the expected prolonged half-lives of the mAbs. Except for one SAE, one Grade 4 elevation of creatine phosphokinase, and one Grade 3 elevation of triglycerides, all deemed as not related to study drugs, all AEs reported were Grade 1-2 in severity, with the majority being isolated asymptomatic transient laboratory

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

abnormalities. There were no safety concerns regarding vital signs or ECGs. The safety observations in these phase 1 studies are consistent with the expected safety profile of human IgG1 mAbs in healthy subjects with no endogenous target. With YTE modification, both BRII-196 and BRII-198 demonstrated anticipated 2-3 folds half-life extension in healthy adult subjects. In comparison with BRII-198, the relatively shorter half-life observed with BRII-196 correlates with slightly higher systemic clearance. As both antibodies showed comparable increased binding affinities to human and cynomolgus monkey FcRns at pH 6.0 in vitro (unpublished data), different molecular properties such as charge variants, glycan profiles, and overall thermal stability might contribute to the observed differences. With up to a 3week optimal treatment window for neutralizing antibodies for COVID-19 patients, both antibodies are expected to provide comparable target coverage at the same dose level. BRII-196 and BRII-198 have several advantages that may facilitate their use for the treatment and prevention of SARS-COV-2 infections. First, mAbs targeting specific viral epitopes, including BRII-196 and BRII-198, belong to a platform technology associated with a favorable safety profile. Findings regarding safety and tolerability in phase 1 trials of BRII-196 and BRII-198 are consistent with the expectation, which support an expedited development towards approval for future clinical use. Second, targeting distinct viral epitopes in the RBD of SARS-COV-2 spike protein noncompetitively, BRII-196 and BRII-198 can be used in combination to provide additive antiviral effect, reduce the generation of resistant viruses to treatment, and retain activity against emergent naturally occurring variants as mentioned above. Third, BRII-196 and BRII-198 are engineered with YTE substitution in the Fc region to allow an extended half-life, demonstrated in the pharmacokinetic findings from both

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

phase 1 studies, with which BRII-196 and BRII-198 can potentially maintain an adequate drug coverage over an extended period of time and subsequently are better positioned for prophylactic use. Lastly, while YTE improves the half-life of the antibody, it also reduced binding activity of BRII-196 and BRII-198 against human Fey receptors, thereby minimizing the potential risk of Fe-mediated antibody dependent enhancement of diseases. In summary, BRII-196 and BRII-198 were generally safe and well-tolerated in healthy adult participants. Pharmacokinetic and immunogenicity assessments demonstrated linear pharmacokinetics with prolonged half-lives and no ADA development up to 180 days after a single dose. These findings support further development of BRII-196 and BRII-198 for the treatment and prophylaxis of SARS-COV-2 infection in the pandemic outbreak. BRII-196 and BRII-198 combination is currently under development in ACTIV-2, a platform phase 2/3 clinical study, for treatment of COVID-19 in outpatients [25]. **Supplementary Materials and Data** Supplementary materials and data are available at *The Journal of Infectious Diseases* online. Consisting of materials and data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author. Acknowledgment. The authors thank all the study participants in these clinical studies, without whom the studies would not have been possible. We thank Dr Yibo Zhou, Jianmin Jing, and

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

Yonghong Mang, for their contributions in the studies. We also thank D.Margolis for criticically reviewing the manuscript and Dr. Chan Gao for her assistance with formatting/editing and submission. Financial support. These trials were sponsored by TSB Therapeutics, a subsidiary company of Brii Biosciences, Y.Z., J.M., Y.L., Y.Y.L., M.W., C.L., L.Y., and Q.Z. are employees of Brii Biosciences. Y.Z. and Q.Z. are employees of TSB Therapeutics. F.J.Z. received support from TSB for participation as a principal investigator in the study. Author contributions: Brii Biosciences was involved in and the study design, collection, analysis and interpretation of data, the writing of this report, and the decision to submit this manuscript for publication. F.J.Z., X.H.H, D.Z., and W.Z. reviewed protocol, and were responsible for study implementation and data collection at the study site. All authors at Brii Bioscienecs had access to all study data for review, participated in interpretation of the data and in drafting and revising the article for important intellectual content, and provided final approval of the submitted manuscript. All authors assume responsibility for the integrity and completeness of the reported data. Y.Z., J.M., Y.L., and Q.Z prepared the manuscript. Potential conflicts of interest. Y.Z., J.M., Y.L., Y.L., M.W., C.L., L.Y., and Q.Z. are employees of Brii Biosciences. Y.Z. and Q.Z. are employees of TSB Therapeutics. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. References Johns_Hopkins_Coronavirus_Resource_Center. 1. COVID-19 Мар. Available at: https://coronavirus.jhu.edu/map.html. Accessed Mar 17 2021. 2. Cao B, Wang Y, Wen D, et al. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med 2020; 382:1787-99. 3. SolidarityTrialConsortium WHO, Pan H, Peto R, et al. Repurposed Antiviral Drugs for Covid-19

- Interim WHO Solidarity Trial Results. N Engl J Med **2021**; 384:497-511.
- 4. Libster R, Pérez Marc G, Wappner D, et al. Early High-Titer Plasma Therapy to Prevent Severe
- 323 Covid-19 in Older Adults. N Engl J Med **2021**; 384:610-8.
- 5. Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the Treatment of Covid-19 Final Report.
- 325 N Engl J Med **2020**; 383:1813-26.
- 326 6. Group RC, Horby P, Lim WS, et al. Dexamethasone in Hospitalized Patients with Covid-19. N
- 327 Engl J Med **2021**; 384:693-704.
- 328 7. Simonovich VA, Burgos Pratx LD, Scibona P, et al. A Randomized Trial of Convalescent Plasma
- 329 in Covid-19 Severe Pneumonia. N Engl J Med **2021**; 384:619-29.
- 330 8. Jin Y, Lei C, Hu D, Dimitrov DS, Ying T. Human monoclonal antibodies as candidate therapeutics
- against emerging viruses. Front Med **2017**; 11:462-70.
- 9. Chen P, Nirula A, Heller B, et al. SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients
- 333 with Covid-19. N Engl J Med **2021**; 384:229-37.
- 334 10. Weinreich DM, Sivapalasingam S, Norton T, et al. REGN-COV2, a Neutralizing Antibody
- Cocktail, in Outpatients with Covid-19. N Engl J Med **2021**; 384:238-51.
- 336 11. Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19
- 337 Vaccine. N Engl J Med **2020**; 383:2603-15.
- 338 12. Baden LR, El Sahly HM, Essink B, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2
- 339 Vaccine. N Engl J Med **2021**; 384:403-16.
- 13. Liu H, Wei P, Zhang Q, et al. 501Y.V2 and 501Y.V3 variants of SARS-CoV-2 lose binding to
- Bamlanivimab in vitro. bioRxiv [Preprint] February 16, 2021 [cited 2021 Apr 8]. Available from:
- 342 https://doi.org/10.1101/2021.02.16.431305


- 343 14. Wu K, Werner AP, Koch M, et al. Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine.
- 344 N Engl J Med 2021.
- 345 15. Ju B, Zhang Q, Ge J, et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection.
- 346 Nature 2020; 584:115-9.
- 347 16. Wang R, Zhang Q, Ge J, et al. SARS-CoV-2 variants resist antibody neutralization and broaden
- 348 host ACE2 usage. bioRxiv [Preprint] March 15, 2021 [cited 2021 Apr 8]. Available from:
- 349 https://doi.org/10.1101/2021.03.09.434497.
- 350 17. Wang P, Nair MS, Liu L, et al. Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7.
- 351 bioRxiv [Preprint] January 26, 2021 [cited 2021 Apr 8]. Available from:
- 352 https://doi.org/10.1101/2021.01.25.428137.
- 353 18. Robbie GJ, Criste R, Dall'acqua WF, et al. A novel investigational Fc-modified humanized
- 354 monoclonal antibody, motavizumab-YTE, has an extended half-life in healthy adults. Antimicrob
- 355 Agents Chemother 2013; 57:6147-53.
- 356 19. Saunders KO. Conceptual Approaches to Modulating Antibody Effector Functions and
- 357 Circulation Half-Life. Front Immunol 2019; 10:1296.
- 358 20. Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, Function, and
- 359 Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell 2020; 181:281-92.e6.
- 360 21. Ge J, Wang R, Ju B, et al. Antibody neutralization of SARS-CoV-2 through ACE2 receptor
- mimicry. Nature communications 2021; 12:250.
- 362 22. Liu Y, Liu J, Xia H, et al. Neutralizing Activity of BNT162b2-Elicited Serum. New England Journal
- 363 of Medicine 2021; 0:null.
- 364 23. Madhi SA, Baillie V, Cutland CL, et al. Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine

against the B.1.351 Variant. New England Journal of Medicine 2021; 0:null.

24. Moruf A. Fact Sheet For Health Care Providers Emergency Use Authorization (EUA) Of Bamlanivimab. U.S. Food and Drug Administration, 2021:26.

25. Large clinical trial will test combination monoclonal antibody therapy for mild/moderate COVID-19. Available at: https://www.nih.gov/news-events/news-releases/large-clinical-trial-will-test-combination-monoclonal-antibody-therapy-mild-moderate-covid-19. Accessed March 24 2021.

Figure 1 Trial Profiles






Figure 2. Observed Mean (±Standard Deviation) Serum Concentration - Time Profiles of BRII-196 and BRII-198 Following A Single Intravenous Infusion Administration to The Healthy Adult Subjects




 Table 1
 Participant Demographics and Baseline Characteristics

	BRII-196-001				BRII-198-001			
	750 mg	1500 mg	3000 mg	Placebo	750 mg	1500 mg	3000 mg	Placebo
	(n=3)	(n=6)	(n=3)	(n=4)	(n=3)	(n=7)	(n=3)	(n=4)
Median age, years	22.0	32.5	34.0	33.5	30.0	33.0	30.0	37.5
Men	3 (100%)	4 (67%)	3 (100%)	3 (75%)	2 (67%)	7 (100%)	3 (100%)	3 (75%)
Women	0	2 (33%)	0	1 (25%)	1 (33%)	0	0	1 (25%)
Race								
Han, Chinese	3 (100%)	6 (100%)	2 (67%)	3 (75%)	3 (100%)	6 (86%)	3 (100%)	4 (100%)
Other, Chinese	0	0	1 (33%)	1 (25%)	0	1 (14%)	0	0
Median body-mass index, kg/m ²	22.80	21.15	21.60	22.90	23.70	21.00	22.30	23.10

Table 2 Summary of Adverse Events of BRII-196-001 Study

	BRII-196 750mg (n=3)	BRII-196 1500mg (n=6)	BRII-196 3000mg (n=3)	Placebo (n=4)
Participants with any TEAE	3 (100%)	5 (83%)	2 (67%)	4 (100%)
Participants with Grade 1 TEAE	3 (100%)	5 (83%)	2 (67%)	4 (100%)
Participants with Grade 2 TEAE	1 (33%)	3 (50%)	0	2 (50%)
Participants with Grade 3 or above TEAE	0	0	0	0
Participants with serious TEAE	0	0	0	0
Participants with infusion reaction TEAE	0	0	0	0
Participants with TEAEs related to study drug	1 (33%)	3 (50%)	0	0
Participants with any TEAE leading to discontinuation of study drug	0	0	0	0
Death	0	0	0	0
Number of participants with AEs by MedDR	A SOC a			
Investigations	3 (100%)	4 (67%)	2 (67%)	4 (100%)
Infections and infestations	1 (33%)	0	0	2 (50%)

TEAE=treatment-emergent adverse event. SOC=system organ class.

Participants who experienced the same AE on more than one occasion (based on the specific category) are counted once in each relevant category. Percentages are based on the number of participants in the treatment group.

^a Only SOCs experienced by ≥ 2 participant or with the maximum severity category \geq Grade 2 are included.

Table 3 Summary of Adverse Events of BRII-198-001 Study

	BRII-198 750mg (n=3)	BRII-198 1500mg (n=6)	BRII-198 3000mg (n=3)	Placebo (n=4)
Participants with any TEAE	3 (100%)	5 (83%)	0	4 (100%)
Participants with Grade 1 TEAE	2 (67%)	5 (83%)	0	3 (75%)
Participants with Grade 2 TEAE	1 (33%)	0	0	1 (25%)
Participants with Grade 3 or above TEAE	0	2a (33%)	0	1 ^b (25%)
Participants with serious TEAE	0	0	0	1 ^b (25%)
Participants with infusion reaction TEAE	0	0	0	0
Participants with TEAEs related to study drug	2 (67%)	1 (17%)	0	0
Participants with any TEAE leading to discontinuation of study drug	0	0	0	0
Death	0	0	0	0
Number of participants with AEs by SOC ^c				
Investigations	3 (100%)	4 (67%)	0	3 (75%)
Gastrointestinal disorders	1 (33%)	1 (17%)	0	0
Injury, poisoning and procedural complications	0	0	0	1 (25%)

TEAE=treatment-emergent adverse event. SOC=system organ class.

Participants who experienced the same AE on more than one occasion (based on the specific category) are counted once in each relevant category. Percentages are based on the number of participants in the treatment group.

^a 1 participant had an elevated blood creatine phosphokinase of Grade 4 after excessive exercise, and 1 participant had an increased blood triglycerides of Grade 3 on Day 181. Both events were not considered as related to the study drug by the investigators and normalized within 1-3 weeks.

^b 1 participant receiving placebo had a serious TEAE (bilateral traumatic foot fracture leading to hospitalization, which was also reported as a Grade 3 TEAE). The participant recovered after surgery.

^c Only SOCs experienced by ≥ 2 participant or with the maximum severity category \geq Grade 2 are included.

Table 4 BRII-196 and BRII-198 Pharmacokinetic Parameters Following A Single Intravenous Infusion Administration to The Healthy Adult Participants

Antibody	Dose	Number o	f C _{max}	T_{max}	t _{1/2}	CL	V_{ss}	AUC _{last}	AUC _{inf}
Antibody	(mg)	Subject	$(\mu g/mL)$	(hour)	(day)	(mL/day)	(L)	$(\text{day*}_{\mu}\text{g/mL})$	(day*µg/mL)
	750	3	268 (19.9)	4.6	48.6 (4.56)	84.7 (10.5)	5.34 (0.500)	8240 (764)	8940 (1040)
BRII-196	1500	6	584 (75.1)	5.4	46.0 (8.09)	72.4 (8.40)	4.50 (0.208)	19300 (2430)	20900 (2380)
	3000	3	1300 (91.7)	6.6	44.6 (6.75)	72.2 (4.11)	4.35 (0.289)	38900 (2510)	41700 (2300)
	750	3	244 (35.5)	4.7	75.9 (8.97)	59.4 (5.54)	6.17 (0.760)	10400 (911)	12700 (1240)
BRII-198	1500	6	509 (107)	5.4	72.2 (8.45)	57.4 (9.50)	5.76 (0.981)	20900 (2950)	26800 (4700)
	3000	3	1017 (149)	6.8	83.0 (37.6)	53.9 (8.90)	6.07 (2.20)	42800 (9680)	56600 (8900)

SD=standard deviation, C_{max} =observed maximum serum concentration, T_{max} =time to reach observed maximum serum concentration, $t_{1/2}$ =terminal half-life, CL=systemic clearance, V_{ss} =volume of distribution at steady state, AUC_{last} =area under the concentration–time curve from time zero to the last measurable concentration, AUC_{inf} =area under the concentration–time curve from time zero to infinity. All parameters are reported in three significant figures except T_{max} that is reported with median values.

Supplementary Tables

Supplementary Table 1. Infusion Related Parameters

Antibody	Dose	Number of	Total Volume Infused	Total Infusion Duration
Antibody	Dosc	Participants	(ml, median [min, max])	(h, median [min, max])
BRII-196	750 mg	3	114 (110, 116)	1.57 (1.53, 1.57)
	1500 mg	6	250 (250, 250)	2.32 (2.27, 2.43)
	3000 mg	3	500 (500, 500)	3.60 (3.58, 3.70)
	Placebo	4	250 (125, 500)	2.30 (1.55, 3.65)
BRII-198	750 mg	3	125 (125, 125)	1.67 (1.65, 1.70)
	1500 mg	6	250 (250, 250)	2.33 (2.28, 2.43)
	3000 mg	3	500 (500, 500)	3.73 (3.70, 3.75)
	Placebo	4	250 (125, 500)	2.32 (1.67, 3.73)
			•	

Supplementary Table 2. Adverse Events by System Organ Class and Preferred Term

Antibody	System Organ Class	750 mg	1500 mg	3000 mg	Placebo
	Preferred Term	(n=3)	(n=6)	(n=3)	(n=4)
BRII-196	Investigations	3 (100%)	4 (67%)	2 (67%)	4 (100%)
	White blood cell count decreased	1 (33%)	3 (50%)	0	1 (25%)
	Blood triglycerides increased	1 (33%)	0	1 (33%)	2 (50%)
	Neutrophil count decreased	1 (33%)	2 (33%)	0	1 (25%)
	Blood uric acid increased	1 (33%)	1 (17%)	1 (33%)	0
	Alanine aminotransferase increased	1 (33%)	0	0	1 (25%)
	Blood bilirubin increased	0	1(17%)	1 (33%)	0
	Low density lipoprotein increased	0	0	0	1 (25%)
	Lymphocyte percentage decreased	0	1 (17%)	0	0
	Monocyte count decreased	0	0	0	1 (25%)
	Neutrophil count increased	0	1 (17%)	0	0
	Platelet count increased	1 (33%)	0	0	0
	White blood cells urine positive	0	0	0	1 (25%)
	Infections and infestations	1 (33%)	0	0	2 (50%)
	Nasopharyngitis	1 (33%)	0	0	1 (25%)
	Periodontitis	1 (33%)	0	0	0
	Tooth infection	0	0	0	1 (25%)
	Gastrointestinal disorders	0	1 (17%)	0	0
	Diarrhoea	0	1 (17%)	0	0
	Musculoskeletal and connective tissue	e0	1 (17%)	0	0
	disorders				
	Pain in extremity	0	1 (17%)	0	0
BRII-198	Investigations	3 (100%)	4 (67%)	0	3 (75%)
	Blood triglycerides increased	0	4 (67%)	0	2 (50%)

Antibody	System Organ Class	750 mg	1500 mg	3000 mg	Placebo
	Preferred Term	(n=3)	(n=6)	(n=3)	(n=4)
	Blood bilirubin increased	1 (33%)	2 (33%)	0	0
	White blood cell count decreased	1 (33%)	1 (17%)	0	1 (25%)
	Alanine aminotransferase increase	d 1 (33%)	1 (17%)	0	0
	Blood creatine phosphokinas	se0	1 (17%)	0	0
	increased				
	Blood uric acid increased	0	0	0	1 (25%)
	Aspartate aminotransferas	se0	1 (17%)	0	0
	increased				
	Injury, poisoning and procedura	al0	0	0	1 (25%)
	complications				
	Foot fracture	0	0	0	1 (25%)
	Ear and labyrinth disorders	0	0	0	1 (25%)
	Cerumen impaction	0	0	0	1 (25%)
	Gastrointestinal disorders	1 (33%)	1 (17%)	0	0
	Abdominal pain upper	1 (33%)	0	0	0
	Constipation	0	1 (17%)	0	0
	Infections and infestations	0	0	0	1 (25%)
	Otitis externa	0	0	0	1 (25%)
	Musculoskeletal and connective tissu	ie0	0	0	1 (25%)
	disorders				
	Arthralgia	0	0	0	1 (25%)

Participants who experienced the same AE on more than one occasion (based on the specific category) are counted once in each relevant category. Percentages are based on the number of participants in the treatment group.

Supplementary Table 3. Treatment-related Adverse Events by Preferred Term.

Antibody	Preferred Term	750 mg	1500 mg	3000 mg	Placebo
		(n=3)	(n=6)	(n=3)	(n=4)
BRII-196	White blood cell count decreased	0	1 (17%)	0	0
	Neutrophil count decreased	0	1 (17%)	0	0
	Alanine aminotransferase increased	1 (33%)	0	0	0
	Blood bilirubin increased	0	1 (17%)	0	0
BRII-198	Alanine aminotransferase increased	1 (33%)	0	0	0
	Blood bilirubin increased	1 (33%)	1 (17%)	0	0

Participants who experienced the same AE on more than one occasion (based on the specific category) are counted once in each relevant category. Percentages are based on the number of participants in the treatment group.

Supplementary Materials

Inclusion and Exclusion Criteria for BRII-196-001 and BRII-198-001 Studies Inclusion Criteria

Subjects are eligible to be included in the study only if all of the following criteria apply:

Age

1. Subject must be 18 to 49 years of age inclusive, at the time of signing the informed consent.

Type of Subjects

2. Subjects who are healthy as determined by medical evaluation including medical history, full physical examination, laboratory tests, and cardiac monitoring using 12-lead ECG, and have venous access sufficient to allow for blood sampling as per the protocol.

Weight

3. Body weight ≤100 kg and body mass index (BMI) within the range of 19.0-24.0kg/m² (inclusive). The weight of male subjects shall be no less than 50kg, and that of female subjects shall be no less than 45kg.

Sex

4. Male and female

Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. Male subjects:

- i. Male subjects with female partners of childbearing potential must agree to meet one of the following contraception requirements from the time of study agent administration through the end of the study:
 - total abstinence, or
 - vasectomy with documentation of azoospermia, or
 - barrier form of contraception with spermicide, or
 - female partner use of an intrauterine device or hormonal contraceptives including oral, implantable, injectable or transdermal contraceptives within 30 days prior to male subject signing the informed consent form (ICF).
- ii. Male subjects must also agree not to donate sperm through the end of the study.

Female subjects:

- i. A female subject is eligible to participate if she is:
 - of non-childbearing potential, defined as premenarchal, or premenopausal with a documented hysterectomy, or bilateral tubal ligation or oophorectomy.
 - of childbearing potential, not breastfeeding and agrees to use one of the following acceptable methods of contraception through the end of the study:
 - total abstinence, or

- barrier form of contraception such as condom or occlusive cap with spermicide, or
- an intrauterine device, or hormonal contraceptives including oral, implantable, injectable or transdermal contraceptives initiated at least within 30 days prior to signing the ICF.
- ii. Woman of Childbearing Potential* (WOCBP) must have a negative serum pregnancy test at screening and a negative serum pregnancy test on Day 1 prior to study treatment (within 24 hours) administration.

Error! Reference source not found.

Informed Consent

5. Capable of giving signed informed consent as described in **Error! Reference source not found.** the protocol which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.

Other Inclusions

- 6. Agrees to not donate blood during the duration of the study.
- 7. Agrees not to increase physical activity for 4 weeks after study agent administration.

Exclusion Criteria

Subjects are excluded from the study if any of the following criteria apply:

Medical Conditions

- Significant history or clinical manifestation of any metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neoplastic (with the exception of basal or squamous cell cancer), neurological, or psychiatric disorder (as determined by the Investigator) capable of significantly altering the absorption of drugs; of constituting a risk when taking the study intervention; or of interfering with the interpretation of the data.
- 2. SARS-COV-2 exposure history or clinical history of COVID-19, including positive COVID-19 RNA test one week before screening or at screening.
- 3. History of previous diagnosis of SARS.
- 4. Any history of a severe allergic reaction with generalized urticaria, angioedema, or anaphylaxis prior to enrollment that has a reasonable risk of recurrence during the study.
- 5. A history of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance, unless approved by the Investigator.
- 6. Bleeding disorder diagnosed by a doctor (e.g., factor deficiency, coagulopathy, or platelet disorder requiring special precautions) or significant bruising or bleeding difficulties with blood draws.
- 7. Any major surgical procedure or hospitalization within 3 months prior to Day 1 or during the study, unless deemed not clinically significant by the Investigator.
- 8. History or presence of an abnormal ECG which, in the Investigator's opinion, is clinically significant.

- 9. History of alcohol or other substance abuse within 1 year prior to screening according to the Diagnostic and Statistical Manual of Mental Disorders, 5th edition criteria, or recent use of drugs of abuse or a positive urine screen for drugs of abuse at screening.
- 10. History of depression or suicidal thoughts and/or behaviors within 1 year prior to screening.
- 11. History of clinically significant chronic liver disease from any cause, presence of hepatitis B surface antigen, hepatitis C virus antibody, human immunodeficiency virus antibody, or syphilis antibody.

Prior/Concomitant Therapy

- 12. Use prescription drugs within 14 days before Day 1, or expected in the course of the study.
- 13. Use of antiplatelet, anticoagulant, or antiepileptic medications within 30 days prior to Day 1, or expected in the course of the study.
- 14. Received immunoglobulin or blood products in the 6 months prior to Day 1, or expected in the course of the study.
- 15. Received any vaccine within 14 days prior to Day 1 through 180 days after dosing in the study.
- 16. Use of over the counter (OTC) medication or herbal remedy, e.g., Traditional Chinese Medicine, within 14 days before Day 1, or expected in the course of the study.

Prior/Concurrent Clinical Study Experience

- 17. Received an investigational agent or provided clinical samples for clinical studies within 90 days or 5 half-lives of the investigational agent whichever is longer, before screening or are active in the follow-up phase of another clinical study involving interventional treatment. Subjects must also agree not to take part in any other study at any time during their participation in this study, inclusive of the follow-up period.
- 18. Previous receipt of a licensed or investigational monoclonal antibody within 5 half-lives or 6 months prior to screening, whichever is longer.

Diagnostic assessments

- 19. Systolic blood pressure >140 mmHg or a diastolic blood pressure of >90 mmHg after approximately 10 minutes resting at screening.
- 20. Calculated glomerular filtration rate of <60 mL/min/1.73m² by estimated glomerular filtration rate (eGFR) using standardized local clinical methodology.

Other Exclusions

- 21. Has an average weekly alcohol intake that exceeds 21 units of alcohol per week (males) or 14 units per week (females) within 30 days prior to screening. One unit: 1 glass of wine 5 oz or 150 mL; 12 oz or 360 mL of beer; 1.5 oz or 45 mL of distilled spirits.
- 22. Are unwilling to stop alcohol consumption within 72 hr prior to Day 1 (as confirmed by alcohol breath screen) or expected for the 24 hr post-dose period.

- 23. Need special dietary restrictions, unless the restrictions are approved by the Investigator and/or Brii Biosciences.
- 24. Any conditions which, in the opinion of the Investigator, would make the subject unsuitable for enrollment or could interfere with the subject's participation in or completion of the study.
- 25. Donated blood within 90 days before screening.

Definition of Woman of Childbearing Potential (WOCBP)

A woman is considered fertile following menarche and until becoming postmenopausal unless permanently sterile (see below).

If fertility is unclear (e.g., amenorrhea in adolescents or athletes) and a menstrual cycle cannot be confirmed before first dose of study intervention, additional evaluation should be considered.

Women in the following categories are not considered WOCBP

- 1. Premenarchal
- 2. Premenopausal female with 1 of the following:
- Documented hysterectomy
- Documented bilateral salpingectomy
- Documented bilateral oophorectomy

For individuals with permanent infertility due to an alternate medical cause other than the above, (e.g., mullerian agenesis, androgen insensitivity), Investigator discretion should be applied to determining study entry.

Note: Documentation can come from the site personnel's: review of the subject's medical records, medical examination, or medical history interview.

- 3. Postmenopausal female
- A postmenopausal state is defined as no menses for 12 months without an alternative medical cause.
- A high follicle stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a postmenopausal state in women not using hormonal contraception or hormonal replacement therapy (HRT).
- Females on HRT and whose menopausal status is in doubt will be required to
 use one of the non-estrogen hormonal highly effective contraception methods
 if they wish to continue their HRT during the study. Otherwise, they must
 discontinue HRT to allow confirmation of postmenopausal status before study
 enrollment.